Garlic-derived compound shows potential to improve muscle health during aging

Can a compound derived from a common kitchen ingredient help support muscle health during aging? A new study suggests it can.

The study reveals that S-1-propenyl-L-cysteine (S1PC), a bioactive compound found in aged garlic extract, shows potential anti-aging effects. S1PC promotes inter-organ communication between fat tissue and the brain, ultimately enhancing muscle strength, pointing to its potential in improving muscle frailty in aged individuals.

A collaborative team of researchers in Japan, between the Institute for Research on Productive Aging (IRPA) in Tokyo, a non-profit aging research organization established in 2019, and Wakunaga Pharmaceutical, Co., Ltd. in Hiroshima, a worldwide leading company for products of aged garlic extract, uncovered how the S1PC compound works in the body to influence muscle function during aging. This study will be published online in the journal Cell Metabolism on May 07, 2026.

“During my clinical experience as a physical therapist, I was often frustrated to see older adults lose physical function and vitality simply because they had no specific disease requiring medical treatment. This gap in proactive care has driven my research,” shares Dr. Kiyoshi Yoshioka, one of the equally contributing first authors of this study. “We hope our findings will help improve fitness and muscle strength in older individuals by the simple inclusion of a nutraceutical as part of the daily diet.”

Aging research has gained a lot of traction owing to the increasingly aging population worldwide and the higher healthcare burden associated with increased muscle frailty in older individuals. Drugs that improve age-associated health conditions are costly and unsustainable in the long run. On the other hand, currently existing health diets lack scientific evidence-based backing. To fill this gap, the research team of the IRPA and Wakunaga set out to identify and develop evidence-based anti-aging interventions by investigating natural compounds found in aged garlic extract (AGE).

They investigated S1PC, a naturally occurring compound derived from AGE and discovered that it activates the enzyme liver kinase B1 (LKB1), a key regulator of cellular metabolism. Importantly, S1PC enhances the formation of a protein complex involving LKB1, which leads to activation of the SIRT1 pathway that promotes secretion of extracellular NAMPT (eNAMPT) from adipose (fat) tissue. The enzyme eNAMPT is key to the synthesis of NAD⁺, a small essential molecule involved in cell protection, DNA repair, and energy production.

Rather than acting directly on muscle, eNAMPT within extracellular vesicles (eNAMPT-EVs) released from fat tissue travels through the bloodstream and acts on the hypothalamus, a key regulatory center in the brain. This interaction is associated with increased sympathetic nervous signaling, which contributes to improved muscle function. The findings reveal a novel communication pathway linking fat tissue, the brain, and skeletal muscle, offering new insights into how aging-related functional decline may be regulated.

The functional benefits of S1PC were further evaluated in aged mice. Long-term administration of S1PC reduced frailty scores, increased skeletal muscle force, and restored core body temperature. Notably, a human study showed that S1PC increased eNAMPT levels in circulation, particularly in individuals with sufficient fat tissue. The finding that the distinct effect of S1PC on eNAMPT-EV secretion is conserved between cells, mice, and humans has significant implications for the use of S1PC as a potential anti-aging intervention in humans.

Highlighting the significance of their findings, Dr. Shin-ichiro Imai, the Chairman of the IRPA, says, “Our findings present a previously unrecognized and unique function of S1PC in activating LKB1, and in promoting an inter-organ communication that ameliorates muscle frailty. We anticipate that S1PC is likely to have a broader anti-aging effect that warrants detailed investigation.”

S1PC represents a potential nutraceutical approach to address age-related muscle decline and may complement other approaches, such as NAD⁺-boosting compounds. As a component of traditional medicine, AGE has been consumed for generations with no reports of adverse events, suggesting a favorable safety profile for S1PC. Sharing his future vision, Dr. Imai explains, “We have succeeded in expanding the current understanding of how different organs coordinate responses during aging. Further research is needed to determine improvements in muscle function in humans and to evaluate the long-term effects of S1PC. The presence and possible role of LKB1 in the brain also needs evaluation.”

By revealing how S1PC influences muscle function, this research opens new directions for understanding and potentially addressing the global challenge of age-related decline.

This research will also be presented at FASEB SRC on NAD⁺ Metabolism & Signaling, to be held on June 7-11 in Melbourne, Florida, USA.

***

About Institute for Research on Productive Aging (IRPA) Japan
The institute’s mission is to make Japan a "country of healthy longevity" through cutting-edge research on aging and longevity. The philosophy of IRPA is "Achieving Productive Aging", where productive aging means "maintain mental and physical health for the people, especially the elderly, and to lead productive lives both in their personal lives and in their contributions to society." IRPA promotes scientific research, in collaboration with companies, for the development and social implementation of anti-aging interventions. IRPA also works to develop young researchers with global leadership and shares cutting-edge scientific knowledge with the public and media to raise awareness.

https://www.irpa.ne.jp/

About Dr. Shin-ichiro Imai from Institute for Research on Productive Aging, Japan
Dr. Shin-ichiro Imai is the Theodore & Bertha Bryan Distinguished Professor of Environmental Medicine and Professor of Developmental Biology and Medicine at Washington University School of Medicine, St. Louis, USA. Prior to joining as Assistant Professor in 2001, he did postdoctoral research at the Massachusetts Institute of Technology, making a breakthrough discovery of sirtuins in the field of aging research. He is also a leading figure in the field of mammalian aging and longevity research, and has received many prestigious awards for his contributions. Dr. Imai is the Chairman of the Institute for Research on Productive Aging (IRPA), Tokyo, Japan.

About Dr. Kiyoshi Yoshioka from Institute for Research on Productive Aging, Japan
Dr. Kiyoshi Yoshioka, is a Team Leader at the IRPA with a clinical background as a physical therapist. His research centers on aging, exercise physiology, and the roles of NAD⁺ metabolism and extracellular vesicles in systemic regulation, aiming to bridge the gap between basic geroscience and clinical rehabilitation.

Funding information
This project was carried out under the sponsored research agreement between the IRPA and Wakunaga Pharmaceutical Co., Ltd.